Characterization of an Uncinocarpus reesii-expressed recombinant tube precipitin antigen of Coccidioides posadasii for serodiagnosis
Name:
journal.pone.0221228.pdf
Size:
1.039Mb
Format:
PDF
Description:
Final Published Version
Author
Yu, Jieh-JuenHolbrook, Eric
Liao, Yu-Rou
Zarnowski, Robert
Andes, David R
Wheat, L Joseph
Malo, Joshua
Hung, Chiung-Yu
Affiliation
Univ Arizona, Coll MedIssue Date
2019-08-14
Metadata
Show full item recordPublisher
PUBLIC LIBRARY SCIENCECitation
Yu J-J, Holbrook E, Liao Y-R, Zarnowski R, Andes DR, Wheat LJ, et al. (2019) Characterization of an Uncinocarpus reesii-expressed recombinant tube precipitin antigen of Coccidioides posadasii for serodiagnosis. PLoS ONE 14(8): e0221228. https://doi.org/10.1371/journal.pone.0221228Journal
PLOS ONERights
Copyright © 2019 Yu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Early and accurate diagnosis of coccidioidomycosis, also known as Valley fever, is critical for appropriate disease treatment and management. Current serodiagnosis is based on the detection of patient serum antibodies that react with tube precipitin (TP) and complement fixation (CF) antigens of Coccidioides. IgM is the first class of antibodies produced by hosts in response to coccidioidal insults. The highly glycosylated beta-glucosidase 2 (BGL2) is a major active component of the TP antigen that stimulates IgM antibody responses during early Coccidioides infection. The predominant IgM epitope on BGL2 is a unique 3-O-methylmannose moiety that is not produced by commonly used protein expression systems. We genetically engineered and expressed a recombinant BGL2 (rBGL2ur), derived from Coccidioides, in non-pathogenic Uncinocarpus reesii, a fungus phylogenetically related to the Coccidioides pathogen. The rBGL2ur protein was purified from the culture medium of transformed U. reesii by nickel affinity chromatography, and the presence of 3-O-methyl man nose was demonstrated by gas chromatography. Seroreactivity of the purified rBGL2ur protein was tested by enzyme-linked immunosorbent assays using sera from 90 patients with coccidioidomycosis and 134 control individuals. The sensitivity and specificity of the assay with rBGL2ur were 78.8% and 87.3%, respectively. These results were comparable to those obtained using a proprietary MiraVista Diagnostic (MVD) IgM (63.3% sensitivity; 96.3% specificity), but significantly better than the ID-TP assay using non-concentrated patient sera (33.3% sensitivity; 100% specificity). Expression of rBGL2ur in U. reesii retains its antigenicity for coccidioidomycosis serodiagnosis and greatly reduces biosafety concerns for antigen production, as Coccidioides spp. are biological safety level 3 agents.Note
Open access journalISSN
1932-6203PubMed ID
31412087Version
Final published versionSponsors
National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21A1114762, R01A1135005, R43 A1131868-01]; MiraVista Diagnostics (MVD)ae974a485f413a2113503eed53cd6c53
10.1371/journal.pone.0221228
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2019 Yu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.
Related articles
- Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
- Authors: Lee CC, Chen CW, Yen HK, Lin YP, Lai CY, Wang JL, Groot OQ, Janssen SJ, Schwab JH, Hsu FM, Lin WH
- Issue date: 2024 Dec 1
- Depressing time: Waiting, melancholia, and the psychoanalytic practice of care.
- Authors: Kirtsoglou E, Simpson B, Salisbury L, Baraitser L
- Issue date: 2020
- Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.
- Authors: Harnan S, Kearns B, Scope A, Schmitt L, Jankovic D, Hamilton J, Srivastava T, Hill H, Ku CC, Ren S, Rothery C, Bojke L, Sculpher M, Woods B
- Issue date: 2024 Oct
- Valley fever under a changing climate in the United States.
- Authors: Howard MH, Sayes CM, Giesy JP, Li Y
- Issue date: 2024 Nov
- Genedrive kit for detecting single nucleotide polymorphism m.1555A>G in neonates and their mothers: a systematic review and cost-effectiveness analysis.
- Authors: Shabaninejad H, Kenny RP, Robinson T, Stoniute A, O'Keefe H, Still M, Thornton C, Pearson F, Beyer F, Meader N
- Issue date: 2024 Oct